Skip to main content

Articles

Page 1 of 68

  1. Hepatic, biliary, and pancreatic cancer pose significant challenges in the field of digestive system diseases due to their highly malignant nature. Traditional Chinese medicine (TCM) has gained attention as a ...

    Authors: Junyu Wu, Guoyi Tang, Chien-Shan Cheng, Ranna Yeerken, Yau-Tuen Chan, Zhiwen Fu, Yi-Chao Zheng, Yibin Feng and Ning Wang
    Citation: Molecular Cancer 2024 23:218
  2. Intestinal cancer (IC) poses a significant global health challenge that drives continuous efforts to explore effective treatment modalities. Conventional treatments for IC are effective, but are associated wit...

    Authors: Juan Zhang, Yulin Wu, Yuanyang Tian, Hongxi Xu, Zhi-Xiu Lin and Yan-Fang Xian
    Citation: Molecular Cancer 2024 23:217
  3. Recent advances in cancer research have highlighted the pivotal role of tertiary lymphoid structures (TLSs) in modulating immune responses, particularly in breast cancer (BRCA). Here, we performed an integrate...

    Authors: Shuyu Li, Nan Zhang, Hao Zhang, Zhifang Yang, Quan Cheng, Kang Wei, Meng Zhou and Chenshen Huang
    Citation: Molecular Cancer 2024 23:216
  4. The Nab-paclitaxel combined with gemcitabine (AG) regimen is the main chemotherapy regimen for pancreatic cancer, but drug resistance often occurs. Currently, the ability to promote sensitization in drug-resis...

    Authors: Cheng-Ke Xie, Cheng-Yu Liao, Hong-Yi Lin, Yong-Ding Wu, Feng-Chun Lu, Xiao-Xiao Huang, Zu-Wei Wang, Ge Li, Cai-Feng Lin, Jian-Fei Hu, Yin-Hao Chen, Qiao-Wei Li, Li-Qun Chen, Hui-Xing Chen and Shi Chen
    Citation: Molecular Cancer 2024 23:215
  5. Non-coding RNAs (ncRNAs), including circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs), are unique RNA molecules widely identified in the eukaryotic genome. Their dysregulation has been discovered and...

    Authors: Qian Yi, Jianguo Feng, Weiwu Lan, Houyin shi, Wei Sun and Weichao Sun
    Citation: Molecular Cancer 2024 23:214
  6. The pursuit of innovative therapeutic strategies in oncology remains imperative, given the persistent global impact of cancer as a leading cause of mortality. Immunotherapy is regarded as one of the most promi...

    Authors: Jun-xiao Shi, Zhi-chao Zhang, Hao-zan Yin, Xian-jie Piao, Cheng-hu Liu, Qian-jia Liu, Jia-cheng Zhang, Wen-xuan Zhou, Fu-chen Liu, Fu Yang, Yue-fan Wang and Hui Liu
    Citation: Molecular Cancer 2024 23:213
  7. Colorectal cancer (CRC) is conventionally classified as right sided, left sided, and rectal cancer. Clinicopathological, molecular features and risk factors do not change abruptly along the colorectum, and var...

    Authors: Abhishek Jain, Montana T. Morris, Domenica Berardi, Trisha Arora, Xavier Domingo-Almenara, Philip B. Paty, Nicholas J. W. Rattray, Daniel Kerekes, Lingeng Lu, Sajid A. Khan and Caroline H. Johnson
    Citation: Molecular Cancer 2024 23:211
  8. Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, wh...

    Authors: Sylvia Zöphel, Nadja Küchler, Johanna Jansky, Cora Hoxha, Gertrud Schäfer, Julius J. Weise, Joanne Vialle, Lea Kaschek, Gebhard Stopper, Hermann Eichler, Daniela Yildiz, Alina Moter, Philipp Wendel, Evelyn Ullrich, Claudia Schormann, Torben Rixecker…
    Citation: Molecular Cancer 2024 23:210
  9. BCR-ABL is a constitutively active tyrosine kinase that stimulates multiple downstream signaling pathways to promote the survival and proliferation of chronic myeloid leukemia (CML) cells. The clinical applica...

    Authors: Ke Yang, Kai Fu, Hong Zhang, Xiaokun Wang, Kenneth K.W. To, Caibo Yang, Fang Wang, Zhe-Sheng Chen and Liwu Fu
    Citation: Molecular Cancer 2024 23:209
  10. Non-small cell lung cancer (NSCLC) is typically diagnosed at advanced stages, which limits the effectiveness of therapeutic interventions. The present study aimed to explore the role of the newly identified ci...

    Authors: Meina Jiang, Huihui Bai, Shuai Fang, Chengwei Zhou, Weiyu Shen and Zhaohui Gong
    Citation: Molecular Cancer 2024 23:208
  11. The clinical response rate to immune checkpoint blockade (ICB) therapy in melanoma remains low, despite its widespread use. Circular non-coding RNAs (circRNAs) are known to play a crucial role in cancer progre...

    Authors: Xin Zang, Xiao-Yu He, Cheng-Mei Xiao, Qing Lin, Meng-Yue Wang, Cheng-Yan Liu, Ling-Yi Kong, Zhong Chen and Yuan-Zheng Xia
    Citation: Molecular Cancer 2024 23:207
  12. Chronic myeloid leukemia (CML) typically occurs in late adulthood. Pediatric CML is a rare form of leukemia. In all age groups, the characteristic genetic driver of the disease is the BCR::ABL1 fusion gene. Howev...

    Authors: Manuela Krumbholz, Anna Dolnik, Eric Sträng, Tabita Ghete, Sabrina Skambraks, Stephan Hutter, Alfred Simonis, Frank Stegelmann, Meinolf Suttorp, Anselm H.C. Horn, Heinrich Sticht, Torsten Haferlach, Lars Bullinger and Markus Metzler
    Citation: Molecular Cancer 2024 23:206
  13. Growth hormone-secreting pituitary neuroendocrine tumors can be pathologically classified into densely granulated (DGGH) and sparsely granulated types (SGGH). SGGH is more aggressive and associated with a poor...

    Authors: Yunzhi Zou, Xiaoqiong Bao, Depei Li, Zhen Ye, Rong Xiang, Yuanzhong Yang, Zhe Zhu, Ziming Chen, Lingxing Zeng, Chunling Xue, Hongzhe Zhao, Boyuan Yao, Qilin Zhang, Zeming Yan, Zekun Deng, Jintong Cheng…
    Citation: Molecular Cancer 2024 23:205
  14. Several fusion oncogenes showing a higher incidence in pediatric acute myeloid leukemia (AML) are associated with heterogeneous megakaryoblastic and other myeloid features. Here we addressed how developmental ...

    Authors: Verónica Alonso-Pérez, Klaudia Galant, Fabien Boudia, Elie Robert, Zakia Aid, Laurent Renou, Vilma Barroca, Saryiami Devanand, Loélia Babin, Virginie Rouiller-Fabre, Delphine Moison, Didier Busso, Guillaume Piton, Christophe Metereau, Nassera Abermil, Paola Ballerini…
    Citation: Molecular Cancer 2024 23:204
  15. Metastasis has been one of the primary reasons for the high mortality rates associated with tumours in recent years, rendering the treatment of current malignancies challenging and representing a significant c...

    Authors: Jiachi Jia, Yuhang Wang, Mengjia Li, Fuqi Wang, Yingnan Peng, Junhong Hu, Zhen Li, Zhilei Bian and Shuaixi Yang
    Citation: Molecular Cancer 2024 23:200
  16. Tumor cells remodel the phenotype and function of tumor microenvironment (TME) cells to favor tumor progression. Previous studies have shown that neutrophils in TME are polarized to N2 tumor-associated neutrop...

    Authors: Jiahui Zhang, Dan Yu, Cheng Ji, Maoye Wang, Min Fu, Yu Qian, Xiaoxin Zhang, Runbi Ji, Chong Li, Jianmei Gu and Xu Zhang
    Citation: Molecular Cancer 2024 23:198
  17. Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors ...

    Authors: Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine A. Bellera, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind…
    Citation: Molecular Cancer 2024 23:197
  18. Colitis-associated colorectal cancer (CAC) frequently develops in patients with inflammatory bowel disease (IBD) who have been exposed to a prolonged state of chronic inflammation. The i...

    Authors: Yonger Chen, Jian Liang, Shuxian Chen, Nan Lin, Shuoxi Xu, Jindian Miao, Jing Zhang, Chen Chen, Xin Yuan, Zhuoya Xie, Enlin Zhu, Mingsheng Cai, Xiaoli Wei, Shaozhen Hou and Hailin Tang
    Citation: Molecular Cancer 2024 23:196
  19. Authors: Qing Shi, Yasheng Zhu, Jian Ma, Kun Chang, Dongling Ding, Yang Bai, Kun Gao, Pingzhao Zhang, Ren Mo, Kai Feng, Xiaying Zhao, Liang Zhang, Huiru Sun, Dongyue Jiao, Yingji Chen, Yinghao Sun…
    Citation: Molecular Cancer 2024 23:194

    The original article was published in Molecular Cancer 2019 18:170

  20. CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity of CD8+ tumour infiltrating lymphocyt...

    Authors: Yikan Sun, Eloy Yinwang, Shengdong Wang, Zenan Wang, Fangqian Wang, Yucheng Xue, Wenkan Zhang, Shenzhi Zhao, Haochen Mou, Shixin Chen, Lingxiao Jin, Binghao Li and Zhaoming Ye
    Citation: Molecular Cancer 2024 23:193
  21. Osteosarcoma is the most common primary bone cancer in children and young adults. Limited progress has been made in improving the survival outcomes in patients with osteosarcoma over the past four decades. Esp...

    Authors: Shengnan Yu and Xudong Yao
    Citation: Molecular Cancer 2024 23:192
  22. Cancer-associated fibroblasts (CAFs) are a diverse stromal cell population within the tumour microenvironment, where they play fundamental roles in cancer progression and patient prognosis. Multiple lines of e...

    Authors: Zhengjun Lin, Guoqing Li, Ke Jiang, Zhihong Li and Tang Liu
    Citation: Molecular Cancer 2024 23:191
  23. Epigenetic alterations, such as those in chromatin structure and DNA methylation, have been extensively studied in a number of tumor types. But oral cancer, particularly oral adenocarcinoma, has received far l...

    Authors: Yue Xue, Lu Liu, Ye Zhang, Yueying He, Jingyao Wang, Zicheng Ma, Tie-jun Li, Jianyun Zhang, Yanyi Huang and Yi Qin Gao
    Citation: Molecular Cancer 2024 23:190
  24. Liver cancer is a global health challenge, causing a significant social-economic burden. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is highly heterogeneous in terms o...

    Authors: Yau-Tuen Chan, Cheng Zhang, Junyu Wu, Pengde Lu, Lin Xu, Hongchao Yuan, Yibin Feng, Zhe-Sheng Chen and Ning Wang
    Citation: Molecular Cancer 2024 23:189
  25. Triple negative breast cancer (TNBC) is a particularly lethal breast cancer (BC) subtype driven by cancer stem cells (CSCs) and an immunosuppressive microenvironment. Our study reveals that nucleus accumbens a...

    Authors: Chrispus Ngule, Ruyi Shi, Xingcong Ren, Hongyan Jia, Felix Oyelami, Dong Li, Younhee Park, Jinhwan Kim, Hami Hemati, Yi Zhang, Xiaofang Xiong, Andrew Shinkle, Nathan L. Vanderford, Sara Bachert, Binhua P. Zhou, Jianlong Wang…
    Citation: Molecular Cancer 2024 23:188
  26. The plasma concentrations of acyl coenzyme A binding protein (ACBP, also known as diazepam-binding inhibitor, DBI, or ‘endozepine’) increase with age and obesity, two parameters that are also amongst the most ...

    Authors: Léa Montégut, Peng Liu, Liwei Zhao, María Pérez-Lanzón, Hui Chen, Misha Mao, Shuai Zhang, Lisa Derosa, Julie Le Naour, Flavia Lambertucci, Silvia Mingoia, Uxía Nogueira-Recalde, Rafael Mena-Osuna, Irene Herranz-Montoya, Nabil Djouder, Sylvain Baulande…
    Citation: Molecular Cancer 2024 23:187
  27. Peritumoral hepatocytes are critical components of the liver cancer microenvironment, However, the role of peritumoral hepatocytes in the local tumor immune interface and the underlying molecular mechanisms ha...

    Authors: Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou and Minshan Chen
    Citation: Molecular Cancer 2024 23:186
  28. The spatial arrangement of immune cells within the tumor microenvironment (TME) and their interactions play critical roles in the initiation and development of cancer. Several advanced technologies such as ima...

    Authors: Jian-Rong Li, Vikram Shaw, Yupei Lin, Xiang Wang, Muhammad Aminu, Yong Li, Jia Wu, Jianjun Zhang, Christopher I. Amos and Chao Cheng
    Citation: Molecular Cancer 2024 23:185
  29. Great progress has been made in utilizing immune checkpoint blockade (ICB) for the treatment of non-small-cell lung cancer (NSCLC). Therapies targeting programmed cell death protein 1 (PD-1) and its ligand PD-...

    Authors: Bo Wu, Xin Huang, Xiang Shi, Meixi Jiang, Hongxu Liu and Li Zhao
    Citation: Molecular Cancer 2024 23:184
  30. Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is constitutively expressed on various immune cel...

    Authors: Qiang Liu, Yujing Guan and Shenglong Li
    Citation: Molecular Cancer 2024 23:183

    The Correction to this article has been published in Molecular Cancer 2024 23:199

  31. The cancer genome contains several driver mutations. However, in some cases, no known drivers have been identified; these remaining areas of unmet needs, leading to limited progress in cancer therapy. Whole-ge...

    Authors: Ken Asada, Syuzo Kaneko, Ken Takasawa, Kouya Shiraishi, Norio Shinkai, Yoko Shimada, Satoshi Takahashi, Hidenori Machino, Kazuma Kobayashi, Amina Bolatkan, Masaaki Komatsu, Masayoshi Yamada, Mototaka Miyake, Hirokazu Watanabe, Akiko Tateishi, Takaaki Mizuno…
    Citation: Molecular Cancer 2024 23:182
  32. Neuroblastoma (NB) is a heterogeneous embryonal malignancy and the deadliest tumor of infancy. It is a complex disease that can result in diverse clinical outcomes. In some children, tumors regress spontaneous...

    Authors: Thale K. Olsen, Jörg Otte, Shenglin Mei, Bethel Tesfai Embaie, Polina Kameneva, Huaitao Cheng, Teng Gao, Vasilios Zachariadis, Ioanna Tsea, Åsa Björklund, Emil Kryukov, Ziyi Hou, Anna Johansson, Erik Sundström, Tommy Martinsson, Susanne Fransson…
    Citation: Molecular Cancer 2024 23:180
  33. Plenty of circRNAs have been reported to play an important role in colorectal cancer (CRC), while the reason of abnormal circRNA expression in cancer still keep elusive. Here, we found that m7G RNA modificatio...

    Authors: Zhenqiang Sun, Yanxin Xu, Chaohua Si, Xiaoke Wu, Yaxin Guo, Chen Chen and Chengzeng Wang
    Citation: Molecular Cancer 2024 23:179
  34. Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing to this resistance is the epigenetic alteration of gene express...

    Authors: Di Chen, Xinyu Gu, Yeltai Nurzat, Lixia Xu, Xueyuan Li, Lixin Wu, Henan Jiao, Peng Gao, Xuqiang Zhu, Dongming Yan, Shaohua Li and Chen Xue
    Citation: Molecular Cancer 2024 23:178
  35. The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunit...

    Authors: Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, Weixue Wang, Fan Wu, Yumin Wang and Yu Wang
    Citation: Molecular Cancer 2024 23:177
  36. Recent research has uncovered a surprisingly high occurrence of aberrant expression and mutations in the genes that encode subunits of the SWI/SNF chromatin-remodeling complexes (SCRC). Nevertheless, the carci...

    Authors: Kai Zhuang, Lishan Wang, Chengyu Lu, Zhiping Liu, Dongli Yang, Hao Zhong, Jiami Zou, Aamir Fahira, Jiaojiao Wang and Zunnan Huang
    Citation: Molecular Cancer 2024 23:176
  37. In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment effic...

    Authors: Xueting Xia, Zongxin Yang, Qisi Lu, Zhenyun Liu, Lei Wang, Jinwen Du, Yuhua Li, Dong-Hua Yang and Shaojie Wu
    Citation: Molecular Cancer 2024 23:175
  38. The drug efflux transporter P-glycoprotein, encoded by the ABCB1 gene, promotes acquired chemoresistance. We explored the presence and clinical relevance of circulating cell-free ABCB1 transcripts (cfABCB1tx) in ...

    Authors: Franziska Maria Schwarz, Jan Dominik Kuhlmann, Jorrin Kämpfer, Anna Klimova, Daniel Martin Klotz, Lisa Freitag, Pia Herrmann, Viktoria Zinnow, Janice Smith, Theresia Scheller, Wolfgang Walther, Pauline Wimberger and Ulrike Stein
    Citation: Molecular Cancer 2024 23:174
  39. Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness or subopti...

    Authors: Yibo Gao, Dandan Cao, Mengfan Li, Fuqiang Zhao, Pei Wang, Shiwen Mei, Qianqian Song, Pei Wang, Yanli Nie, Wei Zhao, Sizhen Wang, Hai Yan, Xishan Wang, Yuchen Jiao and Qian Liu
    Citation: Molecular Cancer 2024 23:173
  40. Exosomes mediate cell-to-cell crosstalk involving a variety of biomolecules through an intricate signaling network. In recent years, the pivotal role of exosomes and their non-coding RNAs cargo in the developm...

    Authors: Margherita Luongo, Pasqualina Laurenziello, Giuseppe Cesta, Anna Maria Bochicchio, Ludmila Carmen Omer, Geppino Falco, Maria Rita Milone, Francesca Cibarelli, Sabino Russi and Simona Laurino
    Citation: Molecular Cancer 2024 23:172
  41. Circular RNAs (circRNAs) are unique noncoding RNAs that have a closed and stable loop structure generated through backsplicing. Due to their conservation, stability and tissue specificity, circRNAs can potenti...

    Authors: Wenjie Zhang, Chen Xu, Zhipeng Yang, Jingshi Zhou, Wei Peng, Xuan Zhang, Haimin Li, Shibin Qu and Kaishan Tao
    Citation: Molecular Cancer 2024 23:171
  42. In the KEYNOTE-811 study, anti-HER2 and immunotherapy treatments resulted in longer survival in HER2-positive gastric cancer patients with CPS ≥ 1, whereas CPS < 1 patients lacked notable benefits. We studied ...

    Authors: Yang Chen, Keren Jia, Xiaoyi Chong, Yi Xie, Lei Jiang, Haoxin Peng, Dan Liu, Jiajia Yuan, Yanyan Li, Xujiao Feng, Yu Sun, Jian Li, Xiaotian Zhang and Lin Shen
    Citation: Molecular Cancer 2024 23:169

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 27.7
    5-year Journal Impact Factor: 31.3
    Source Normalized Impact per Paper (SNIP): 4.737
    SCImago Journal Rank (SJR): 8.222

    Speed 2023
    Submission to first editorial decision (median days): 3
    Submission to acceptance (median days): 91

    Usage 2023
    Downloads: 3,569,666
    Altmetric mentions: 2,070